Several brokerages have updated their recommendations and price targets on shares of Aldeyra Therapeutics (NASDAQ: ALDX) in the last few weeks:

  • 9/14/2017 – Aldeyra Therapeutics had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $14.00 price target on the stock, up previously from $9.00.
  • 9/13/2017 – Aldeyra Therapeutics had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $27.00 price target on the stock, up previously from $12.00.
  • 9/12/2017 – Aldeyra Therapeutics was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.
  • 9/6/2017 – Aldeyra Therapeutics was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 8/17/2017 – Aldeyra Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Aldeyra Therapeutics, Inc. is a biotechnology company. The company’s products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. “
  • 8/10/2017 – Aldeyra Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $4.75 price target on the stock. According to Zacks, “Aldeyra Therapeutics, Inc. is a biotechnology company. The company’s products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. “
  • 8/9/2017 – Aldeyra Therapeutics was given a new $18.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.

Shares of Aldeyra Therapeutics, Inc. (NASDAQ ALDX) traded down 3.27% during midday trading on Tuesday, hitting $7.40. 312,923 shares of the stock traded hands. Aldeyra Therapeutics, Inc. has a 1-year low of $3.80 and a 1-year high of $11.90. The stock has a 50 day moving average of $4.93 and a 200 day moving average of $4.79. The company’s market capitalization is $46.21 million.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.02. Equities research analysts predict that Aldeyra Therapeutics, Inc. will post ($1.63) earnings per share for the current fiscal year.

In related news, major shareholder Life Sciences Maste Perceptive purchased 296,007 shares of the firm’s stock in a transaction that occurred on Friday, June 30th. The shares were bought at an average price of $4.60 per share, for a total transaction of $1,361,632.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 28.40% of the stock is currently owned by company insiders.

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Receive News & Ratings for Aldeyra Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.